Nature Reviews Drug Discovery 17, 783–784 (2018)
In the original version of Figure 1, the label in the Y axis 'T cell-targeted' was incorrect and should be 'T cell-targeted immunomodulator'. The article has been corrected in the online version.
Additional information
The online version of the original article can be found at https://doi.org/10.1038/nrd.2018.167
Rights and permissions
About this article
Cite this article
Tang, J., Pearce, L., O'Donnell-Tormey, J. et al. Erratum: Trends in the global immuno-oncology landscape. Nat Rev Drug Discov 17, 922 (2018). https://doi.org/10.1038/nrd.2018.202
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/nrd.2018.202
This article is cited by
-
Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer
European Journal of Medical Research (2024)
-
Pan-cancer analysis of oncogenic role of CEP55 and experiment validation in clear cell renal cell carcinoma
Scientific Reports (2024)
-
The prognostic and immune significance of SLAMF9 in pan-cancer and validation of its role in colorectal cancer
Scientific Reports (2024)
-
The miR-1185-2-3p—GOLPH3L pathway promotes glucose metabolism in breast cancer by stabilizing p53-induced SERPINE1
Journal of Experimental & Clinical Cancer Research (2021)
-
In silico identification of natural products from Traditional Chinese Medicine for cancer immunotherapy
Scientific Reports (2021)
